Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Dexrazoxane (Savene®) is not recommended for use within NHS Wales for the treatment of anthracycline extravasation due to lack of robust evidence of clinical and cost effectiveness. |
||
|
||
Medicine details |
||
| Medicine name | dexrazoxane (Savene®) | |
| Formulation | 20 mg/ml powder for concentrate and diluent for solution for infusion | |
| Reference number | 109 | |
| Indication | Treatment of anthracycline extravasation |
|
| Company | Topotarget A/S | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 0207 | |
| NMG meeting date | 17/05/2007 | |
| AWMSG meeting date | 12/06/2007 | |
| Ratification by Welsh Government | 30/07/2007 | |
| Date of issue | 10/08/2007 | |